Eyenovia, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson -0.13%163.630.7%$1114.75m
MRKMerck & Co., Inc. -0.65%76.250.7%$1039.37m
PFEPfizer Inc. 0.56%39.640.9%$945.80m
LLYEli Lilly & Co. -0.43%221.711.1%$939.05m
ABBVAbbVie, Inc. -0.11%114.611.9%$738.94m
BMYBristol-Myers Squibb Co. -1.46%65.861.0%$634.76m
AZNAstraZeneca Plc -0.80%57.851.2%$389.61m
OGN -0.78%29.180.0%$288.44m
NVSNovartis AG -0.81%93.150.2%$180.14m
GSKGlaxoSmithKline Plc -1.63%39.130.2%$161.89m
ANVSAnnovis Bio, Inc. -2.87%93.340.0%$157.44m
NOVNNovan, Inc. 0.96%10.495.8%$141.85m
ORPHOrphazyme A/S -8.15%5.990.0%$136.09m
CNSTConstellation Pharmaceuticals, Inc. -0.13%33.760.0%$112.69m
CVACCureVac NV -3.59%57.530.0%$110.29m

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.